
Prime Medicine, Inc. (NASDAQ:PRME – Free Report) – Research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Prime Medicine in a research note issued on Monday, November 16th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.99) per share for the year, up from their previous estimate of ($1.11). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Prime Medicine’s Q4 2026 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.22) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.90) EPS, FY2029 earnings at ($0.94) EPS and FY2030 earnings at ($0.80) EPS.
A number of other research firms have also weighed in on PRME. Citigroup reaffirmed a “market outperform” rating on shares of Prime Medicine in a report on Friday, September 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Prime Medicine in a report on Monday, August 31st. BMO Capital Markets initiated coverage on shares of Prime Medicine in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $9.00 price objective for the company. Chardan Capital reissued a “buy” rating and issued a $7.00 price objective on shares of Prime Medicine in a research report on Friday, September 25th. Finally, Jefferies Financial Group restated a “market outperform” rating on shares of Prime Medicine in a research note on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.86.
Prime Medicine Price Performance
NASDAQ PRME opened at $3.84 on Wednesday. The company’s fifty day simple moving average is $3.73 and its 200-day simple moving average is $3.51. Prime Medicine has a 52 week low of $2.67 and a 52 week high of $5.91.
Prime Medicine (NASDAQ:PRME – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The company had revenue of $4.21 million during the quarter. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 286.97%.
Institutional Trading of Prime Medicine
A number of hedge funds have recently made changes to their positions in PRME. Alphabet Inc. bought a new stake in shares of Prime Medicine in the 2nd quarter worth about $61,116,000. BlackRock Inc. acquired a new stake in shares of Prime Medicine in the 2nd quarter valued at about $35,432,000. ADAR1 Capital Management LLC bought a new position in shares of Prime Medicine during the second quarter worth about $7,371,000. Redmile Group LLC bought a new position in shares of Prime Medicine during the first quarter worth about $5,536,000. Finally, Bank of America Corp DE acquired a new position in Prime Medicine in the second quarter worth about $3,621,000. Institutional investors and hedge funds own 70.37% of the company’s stock.
Key Prime Medicine News
Investors following PRME have been watching these news items:
- Positive Sentiment: HC Wainwright raised several EPS forecasts, implying smaller expected losses. Notable revisions include FY2026 to ($0.99) from ($1.11), Q4 2026 to ($0.26) from ($0.32), and FY2027 to ($0.89) from ($0.91). It maintained its Buy rating and $8 price target. These forecast improvements could support investor sentiment, though Prime Medicine is still expected to report losses. HC Wainwright estimate updates
- Positive Sentiment: HC Wainwright separately reaffirmed its Buy rating and $8 price target for PRME, adding support to the positive analyst view. Prime Medicine stock rating reaffirmed as Buy
- Neutral Sentiment: Prime Medicine presented at the Jefferies Global Healthcare Conference on November 16. The provided transcript listing contains no specific statements or announcements to assess as a stock catalyst. Jefferies conference transcript
About Prime Medicine
Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.
Recommended Stories
- Five stocks we like better than Prime Medicine
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
